ABSTRACT
For decades, the remote island nation of Samoa (pop. ~200,000) has faced endemic typhoid fever despite improvements in water quality, sanitation, and economic development. We recently described the epidemiology of typhoid fever in Samoa from 2008-2019 by person, place, and time; however, the local Salmonella enterica serovar Typhi (S. Typhi) population structure, evolutionary origins, and genomic features remained unknown. Herein, we report whole genome sequence analyses of 306 S. Typhi isolates from Samoa collected between 1983 and 2020. Phylogenetics revealed a dominant population of rare genotypes 3.5.4 and 3.5.3, together comprising 292/306 (95.4%) of Samoan versus 2/4934 (0.04%) global S. Typhi isolates. Three distinct 3.5.4 genomic sub-lineages were identified and their defining polymorphisms were determined. These dominant Samoan genotypes, which likely emerged in the 1970s, share ancestry with other clade 3.5 isolates from South America, Southeast Asia, and Oceania. Additionally, a 106-kb pHCM2 phenotypically-cryptic plasmid, detected earliest in a 1992 Samoan S. Typhi isolate, was identified in 106/306 (34.6%) of Samoan isolates; this is more than double the observed proportion of pHCM2-containing isolates in the global collection. In stark contrast with global S. Typhi trends, resistance-conferring polymorphisms were detected in only 15/306 (4.9%) of Samoan S. Typhi, indicating overwhelming susceptibility to antibiotics that are no longer effective in most of South and Southeast Asia. This country-level genomic framework can help local health authorities in their ongoing typhoid surveillance and control efforts, as well as to fill a critical knowledge gap in S. Typhi genomic data from Oceania.
IMPORTANCE In this study we used whole genome sequencing and comparative genomics analyses to characterize the population structure, evolutionary origins, and genomic features of S. Typhi associated with decades of endemic typhoid fever in Samoa. Our analyses of Samoan isolates from 1983 to 2020 identified a rare S. Typhi population in Samoa that likely emerged around the early 1970s and evolved into sub-lineages that presently dominate. The dominance and persistence of these endemic genotypes in Samoa are not readily explained by any apparent genomic competitive advantage or widespread acquisition of antimicrobial resistance. These data establish the necessary framework for future genomic surveillance of S. Typhi in Samoa for public health benefit.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Bill & Melinda Gates Foundation OPP1194582 (INV-000049) (PI: Prof. Myron M. Levine). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. M. J. S. received research support in part by federal funds from National Institutes of Health under National Institute of Allergy and Infectious Diseases grants F30AI156973 (PI: Michael J. Sikorski) and U19AI110820 (PI: David A. Rasko), as well as National Institute of Diabetes and Digestive and Kidney Diseases training grant T32DK067872 (PI: Jean-Pierre Raufman). M. M. L. is supported in part by the Simon and Bessie Grollman Distinguished Professorship at the University of Maryland School of Medicine. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. M. M. L. reports grants from Bill & Melinda Gates Foundation during the conduct of the study; in addition, M. M. L. has a patent entitled - Broad spectrum vaccine against typhoidal and nontyphoidal Salmonella disease (US 9,011,871 B2) issued. R. M. R.-B. reports grants from Bill & Melinda Gates Foundation, and non-financial support from the Government of Samoa during the conduct of the study. All other authors report no potential conflicts.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received ethical clearance from the Health Research Committee of the Ministry of Health (MoH) of Samoa. The University of Maryland, Baltimore (UMB) Institutional Review Board determined this project, protocol HP-00087489, to be exempt.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All raw sequences and complete assemblies generated in this study have been deposited on GenBank BioProject PRJNA319593 with the accessions listed in Table S1. All assemblies analyzed have been deposited on Figshare (doi: 10.6084/m9.figshare.18665686).
